These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 37173733)

  • 21. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropathology of α-synuclein in Parkinson's disease.
    Choong CJ; Mochizuki H
    Neuropathology; 2022 Apr; 42(2):93-103. PubMed ID: 35362115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.
    Coughlin DG; Hurtig HI; Irwin DJ
    Mov Disord; 2020 Jan; 35(1):5-19. PubMed ID: 31660655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Lewy body formation in Parkinson's disease: neurodegeneration or neuroprotection?].
    Wakabayashi K
    Rinsho Shinkeigaku; 2008 Nov; 48(11):981-3. PubMed ID: 19198138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proposal for a Biologic Staging System of Parkinson's Disease.
    Chahine LM; Merchant K; Siderowf A; Sherer T; Tanner C; Marek K; Simuni T
    J Parkinsons Dis; 2023; 13(3):297-309. PubMed ID: 37066922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. α-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients.
    Manne S; Kondru N; Jin H; Anantharam V; Huang X; Kanthasamy A; Kanthasamy AG
    Mov Disord; 2020 Feb; 35(2):268-278. PubMed ID: 31758740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.
    Arima K; Hirai S; Sunohara N; Aoto K; Izumiyama Y; Uéda K; Ikeda K; Kawai M
    Brain Res; 1999 Oct; 843(1-2):53-61. PubMed ID: 10528110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TIGAR inclusion pathology is specific for Lewy body diseases.
    López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR
    Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathological biochemistry of alpha-synucleinopathy.
    Iwatsubo T
    Neuropathology; 2007 Oct; 27(5):474-8. PubMed ID: 18018483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients.
    Doorn KJ; Moors T; Drukarch B; van de Berg WDj; Lucassen PJ; van Dam AM
    Acta Neuropathol Commun; 2014 Aug; 2():90. PubMed ID: 25099483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders.
    Patterson L; Rushton SP; Attems J; Thomas AJ; Morris CM
    Brain Pathol; 2019 Jul; 29(4):544-557. PubMed ID: 30582885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
    Jellinger KA; Korczyn AD
    BMC Med; 2018 Mar; 16(1):34. PubMed ID: 29510692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral Lewy body pathology in Parkinson's disease and incidental Lewy body disease: four cases.
    Del Tredici K; Duda JE
    J Neurol Sci; 2011 Nov; 310(1-2):100-6. PubMed ID: 21689832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders.
    Saito Y; Shioya A; Sano T; Sumikura H; Murata M; Murayama S
    Mov Disord; 2016 Jan; 31(1):135-8. PubMed ID: 26748832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies.
    Seidel K; Mahlke J; Siswanto S; Krüger R; Heinsen H; Auburger G; Bouzrou M; Grinberg LT; Wicht H; Korf HW; den Dunnen W; Rüb U
    Brain Pathol; 2015 Mar; 25(2):121-35. PubMed ID: 24995389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis of α-Synuclein in Parkinson's Disease: From a Neuron-Glia Crosstalk Perspective.
    Yi S; Wang L; Wang H; Ho MS; Zhang S
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
    Wakabayashi K; Tanji K; Mori F; Takahashi H
    Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.